Apotex Inc.'s proposed copies of Symbravo infringe 75 patents for the migraine drug, Axsome Therapeutics Inc. said in what appears to be its first patent suit since Symbravo’s approval earlier this year.
Axsome alleged Apotex’s generic tablets combining Symbravo’s active ingredients of meloxicam and rizatriptan infringe patents covering the drug’s composition and use in treating acute migraines, according to a complaint filed Sept. 26 in the US District Court for the District of New Jersey.
The US Food and Drug Administration approved Symbravo on Jan. 30 and US sales launched June 10, Apotex said in its quarterly earnings report. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.